AU2015342801A1 - Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma - Google Patents
Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma Download PDFInfo
- Publication number
- AU2015342801A1 AU2015342801A1 AU2015342801A AU2015342801A AU2015342801A1 AU 2015342801 A1 AU2015342801 A1 AU 2015342801A1 AU 2015342801 A AU2015342801 A AU 2015342801A AU 2015342801 A AU2015342801 A AU 2015342801A AU 2015342801 A1 AU2015342801 A1 AU 2015342801A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subject
- day
- cpp
- oat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076980P | 2014-11-07 | 2014-11-07 | |
| US62/076,980 | 2014-11-07 | ||
| PCT/US2015/059738 WO2016073983A2 (en) | 2014-11-07 | 2015-11-09 | Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2015342801A1 true AU2015342801A1 (en) | 2017-05-18 |
Family
ID=55910047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015342801A Abandoned AU2015342801A1 (en) | 2014-11-07 | 2015-11-09 | Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9603820B2 (enExample) |
| EP (1) | EP3215144B1 (enExample) |
| JP (1) | JP6867949B2 (enExample) |
| AU (1) | AU2015342801A1 (enExample) |
| CA (1) | CA2966642C (enExample) |
| ES (1) | ES2882126T3 (enExample) |
| IL (1) | IL252042B (enExample) |
| MX (1) | MX2017006022A (enExample) |
| WO (1) | WO2016073983A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019191525A1 (en) * | 2018-03-29 | 2019-10-03 | Ovid Therapeutics Inc. | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
| US10822301B2 (en) | 2018-04-12 | 2020-11-03 | Northwestern University | 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase |
| CN117550990B (zh) | 2018-05-25 | 2025-09-16 | 西北大学 | 用于合成(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸的工艺 |
| KR102744830B1 (ko) | 2018-06-07 | 2024-12-19 | 오비드 테라퓨틱스 인크. | 발달 장애 치료에 있어서, (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산 및 관련된 화합물들, (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 사이클로펜탄 -1-카르복실산 및 비가바트린의 사용 |
| US11203596B2 (en) * | 2019-02-25 | 2021-12-21 | Northwestern University | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity |
| WO2020206234A1 (en) * | 2019-04-03 | 2020-10-08 | Northwestern University | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase |
| US11993569B2 (en) | 2020-01-23 | 2024-05-28 | Northwestern University | 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases |
| EP4301724A4 (en) * | 2021-03-03 | 2025-05-28 | Northwestern University | (S)-3-AMINO-4,4-DIHALOCYCLOPENT-1-CARBOXYLIC ACID AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE |
| WO2022223969A1 (en) * | 2021-04-20 | 2022-10-27 | Bicycletx Limited | Bicyclic peptide ligands specific for p-selectin |
| AU2022331568A1 (en) * | 2021-08-19 | 2024-03-14 | N1 Life, Inc. | Taxol conjugate compounds, pharmaceutical compositions comprising the same, and methods for their use |
| WO2024196851A1 (en) * | 2023-03-17 | 2024-09-26 | Northwestern University | Bicyclic compounds as inactivators of oat and gaba-at |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| IL177609A (en) | 2006-08-21 | 2015-11-30 | Yaron Ilan | Use of gobacoline or its analogue to produce a drug to treat liver carcinoma |
-
2015
- 2015-11-09 JP JP2017543338A patent/JP6867949B2/ja active Active
- 2015-11-09 EP EP15856956.6A patent/EP3215144B1/en active Active
- 2015-11-09 CA CA2966642A patent/CA2966642C/en active Active
- 2015-11-09 AU AU2015342801A patent/AU2015342801A1/en not_active Abandoned
- 2015-11-09 ES ES15856956T patent/ES2882126T3/es active Active
- 2015-11-09 MX MX2017006022A patent/MX2017006022A/es unknown
- 2015-11-09 US US14/936,153 patent/US9603820B2/en active Active
- 2015-11-09 WO PCT/US2015/059738 patent/WO2016073983A2/en not_active Ceased
-
2017
- 2017-04-30 IL IL252042A patent/IL252042B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3215144B1 (en) | 2021-04-28 |
| MX2017006022A (es) | 2017-11-17 |
| CA2966642A1 (en) | 2016-05-12 |
| EP3215144A2 (en) | 2017-09-13 |
| CA2966642C (en) | 2023-03-28 |
| IL252042B (en) | 2020-05-31 |
| ES2882126T3 (es) | 2021-12-01 |
| IL252042A0 (en) | 2017-06-29 |
| JP2017533964A (ja) | 2017-11-16 |
| EP3215144A4 (en) | 2018-06-20 |
| US20160128958A1 (en) | 2016-05-12 |
| WO2016073983A3 (en) | 2016-08-11 |
| JP6867949B2 (ja) | 2021-05-12 |
| WO2016073983A2 (en) | 2016-05-12 |
| US9603820B2 (en) | 2017-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3215144B1 (en) | Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma | |
| AU2017284160B2 (en) | FXR (NR1H4) modulating compounds | |
| US20200323866A1 (en) | Ezh2 inhibitors for treating lymphoma | |
| US12258336B2 (en) | Preparation of seimicarbazide-sensitive amine oxidase inhibitor and use thereof | |
| US12233128B2 (en) | Degraders that target ALK and therapeutic uses thereof | |
| US20190161442A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| Fan et al. | Design, synthesis, and biological evaluation of a novel indoleamine 2, 3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor | |
| KR20180041234A (ko) | 레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체 | |
| CN112638866A (zh) | 索拉非尼衍生物的共晶体及其制备方法 | |
| Sato et al. | Synthesis, structure-activity relationships, and mechanistic studies of 5-arylazo-tropolone derivatives as novel xanthine oxidase (XO) inhibitors | |
| CN109942630B (zh) | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 | |
| US11426371B2 (en) | Compositions and methods for treating cancer | |
| US12486246B2 (en) | Replication protein A (RPA)-DNA interaction inhibitors | |
| WO2024196851A1 (en) | Bicyclic compounds as inactivators of oat and gaba-at | |
| WO2025250811A1 (en) | Thymidine analogs and methods for their use in the treatments of cancer and other diseases | |
| EP4396166A1 (en) | 2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivatives and their use in the treatment of tumors | |
| HK40097684A (en) | Ezh2 inhibitors for treating lymphoma | |
| WO2024196853A1 (en) | Substituted cyclohexene and cyclohexane inhibitors of ornithine aminotransferase | |
| AU2024278807A1 (en) | Mitochondria specific transcription inhibitors | |
| HK40050156B (en) | Co-crystal of sorafenib derivatives and process for preparation thereof | |
| HK40050156A (en) | Co-crystal of sorafenib derivatives and process for preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |